NCT05611905

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

Phase 1 Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid (11C-PABA)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 13 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The investigators will perform radionuclide PET scans in subjects with infectious diseases to assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging. Tomographic imaging can be used to evaluate disease processes deep within the body, noninvasively and relatively rapidly. The goal is to see if this imaging technique can help differentiate infections from non-infectious processes and also provide information on the causative bacterial class.

Conditions

• Renal Excretion
• Bacterial Infections
• Inflammatory Disease
• Oncologic Disease

Interventions

Type	Name	Description
COMBINATION_PRODUCT	11C-para-aminobenzoic acid PET/CT	A bolus of 20 mCi of 11C-PABA followed by PET/CT
DRUG	Probenecid	Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.

Timeline

• Start date: 2023-12-22
• Primary completion: 2025-11-08
• Completion: 2025-11-08
• First posted: 2022-11-10
• Last updated: 2025-12-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study